NCT01638546 - Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 27, 2012

Primary Completion Date

January 9, 2017

Study Completion Date

March 25, 2026

Conditions

Recurrent Lung Small Cell Carcinoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo Administration

Given PO

DRUG

Temozolomide

Given PO

DRUG

Veliparib

Given PO

Trial Locations (14)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memorial Sloan Kettering Sleepy Hollow, Sleepy Hollow

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

21224

Johns Hopkins Bayview Medical Center, Baltimore

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

23298

VCU Massey Comprehensive Cancer Center, Richmond

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

33612

Moffitt Cancer Center, Tampa

44106

Case Western Reserve University, Cleveland

63110

Washington University School of Medicine, St Louis

77030

M D Anderson Cancer Center, Houston

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH